Article citationsMore>>

Di Nardo, P., de Scordilli, M., Giudici, F., Basile, D., Pastò, B., Rota, S., et al. (2026) Triplet Chemotherapy Combined with Anti Epidermal Growth Factor Receptor Treatment in RAS Wild-Type Colorectal Cancer: A Network Metanalysis. The Oncologist, 31, oyag011.
https://doi.org/10.1093/oncolo/oyag011

has been cited by the following article:

• TITLE: Beyond TNM Staging: Clinical Significance of Combined Molecular Biomarkers (TP53, Ki67, RAS, and MSI) in Colorectal Cancer

  AUTHORS: Taiyan Zhu

  KEYWORDS: Colorectal Cancer, Precision Medicine, TP53, KRAS, Microsatellite Instability, Ki67, Risk Stratification

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.14 No.5, May 7, 2026

  ABSTRACT: Current colorectal cancer management relies on TNM staging and single-gene testing, often failing to capture biological heterogeneity. This study evaluates the synergistic prognostic value of TP53, Ki67, RAS, and MSI in a 120-patient cohort. We identify a high-risk “Triple Hit” phenotype (MSS/RAS-mut/TP53-mut/High-Ki67) that independently predicts poor overall survival, particularly demonstrating significant risk stratification within early-stage disease. Our proposed Combined Molecular Score offers superior prognostic resolution compared to TNM staging alone. This accessible multi-dimensional atlas provides a robust tool for risk assessment, bridging the gap between molecular biology and routine clinical practice while providing a hypothesis-generating framework for future therapeutic intensification.